Radioactive Iodine Therapy in Differentiated Thyroid Cancer: Summary of the Korean Thyroid Association Guidelines 2024 from Nuclear Medicine Perspective, Part-II
10.1007/s13139-024-00886-x
- Author:
So Won OH
1
;
Sohyun PARK
;
Ari CHONG
;
Keunyoung KIM
;
Ji‑In BANG
;
Youngduk SEO
;
Chae Moon HONG
;
Sang‑Woo LEE
Author Information
1. Department of Nuclear Medicine, Seoul National University Boramae Medical Center, Seoul, Korea
- Publication Type:REVIEW
- From:Nuclear Medicine and Molecular Imaging
2025;59(1):8-26
- CountryRepublic of Korea
- Language:English
-
Abstract:
Thyroid cancer, one of the most common endocrine tumors, generally has a favorable prognosis but remains a significant medical and societal concern due to its high incidence. Early diagnosis and treatment of differentiated thyroid cancer (DTC) significantly affect long-term outcomes, requiring the selection and application of appropriate initial treatments to improve prognosis and quality of life. Recent advances in technology and health information systems have enhanced our understanding of the molecular genetics of thyroid cancer, facilitating the identification of aggressive subgroups and enabling the accumulation of research on risk factors through big data. The Korean Thyroid Association (KTA) has revised the “KTA Guidelines on the Management of Differentiated Thyroid Cancers 2024” to incorporate these advances, which were developed by a multidisciplinary team and underwent extensive review and approval processes by various academic societies.This article summarizes the 2024 KTA guidelines for radioactive iodine (RAI) therapy in patients with DTC, written by the Nuclear Medicine members of the KTA Guideline Committee, and covers RAI therapy as initial management of DTC and RAI therapy in advanced thyroid cancer.
